Study of the Mechanism of Antiviral Activity of Cytovir®-3 Against Respiratory Viruses In Vitro

Introduction. The requirements of modern clinical guidelines for the treatment of respiratory viral infections suggest the possibility of identifying a specific viral pathogen. In this regard, the search for drugs with selective activity against respiratory syncytial virus and parainfluenza virus is relevant. The purpose of the work is to study the antiviral activity of the drug Cytovir®-3 in vitro in relation to the cytopathogenic effect of respiratory viruses (parainfluenza virus and respiratory syncytial virus). Material and methods. The antiviral effect of Cytovir®-3 in comparison with Umifenovir against parainfluenza virus and respiratory syncytial virus was studied on Vero cell culture. Drugs were administered 1 hour before (prophylactic regimen) and 1 hour after (treatment regimen) infection of the cell culture with respiratory viruses. The working range of concentrations of the studied drugs was calculated based on the values of 50% cytotoxic concentration calculated based on the results of a quantitative microtetrazole test. Results and discussion. The drug Cytovir®-3 in two schemes of application (therapeutic or prophylactic) showed its antiviral efficacy in vitro against respiratory syncytial virus and parainfluenza virus due in the non-toxic range (0–794 µg/ml). At the same time, the suppressive effect of the drug Cytovir®-3 against the parainfluenza virus begins at lower concentrations of the drug with its early (preventive) introduction into cell culture (250 mcg/ml). Conclusion. Antiviral activity of Cytovir®-3 has been proven in vitro against parainfluenza virus and respiratory syncytial virus. At the same time, in all series of experiments, Cytovir®-3 had a higher index of selectivity of antiviral action than that of the comparison drug Umifenovir.

1. Clinical guidelines: Acute respiratory viral infections (ARVI) in adults. Available at: https://cr.minzdrav.gov.ru/recomend/724_1 (accessed February 17, 2022). (in Russian)

2. Markova T.P., Chuvirov D.G. ORVI: profilaktika i lechenie v epidemicheskiy sezon. Russkii Meditsinskii Zhurnal. 2016; 3: 171–176. (in Russian)

3. Clinical guidelines: Acute respiratory viral infections (ARVI). Available at: https://cr.minzdrav.gov.ru/schema/25_2 (accessed February 17, 2022). (in Russian)

4. Aleksandrovich Yu.S., Kozlova E.M., Novopol'tseva E.G., Novopol'tsev D.E. Ostrye respiratornye infektsii u detei. Oslozhneniya i zhizneugrozhayushchie sostoyaniya: Uchebnoe posobie dlya vrachei. SPb.: SPbGPMU; 2021. (in Russian)

5. Babachenko I.V., Orlova E.D., Lobzin Yu.V. Impact of the COVID-19 pandemic on the seasonality of respiratory syncytial viral infection. Zurnal Infectologii. 2022; 14 (2): 39–46. DOI: https://doi.org/10.22625/2072-6732-2022-14-2-39-46. (in Russian)

6. Summeren van J., Meijer A., Aspelund G. et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Eurosurveillance. 2021; 26 (29): 1–6. doi: 10.2807/1560-7917.ES.2021.26.29.2100639.

7. Foley D.A., Yeoh D.K., Minney-Smith C.A. et al. The interseasonal resurgence of respiratory syncytial virus in australian children following the reduction of coronavirus disease 2019–related public health measures. Clin Infect Dis. 2021 Nov 2; 73 (9): e2829–e2830. doi: 10.1093/cid/ciaa1906.

8. Halabi K.C., Saiman L., Zachariah P. The Epidemiology of respiratory syncytial virus in New York City during the coronavirus disease-2019 pandemic compared with previous years. J Pediatr. 2022; 242: 242–244. doi: 10.1016/j.jpeds.2021.10.057.

9. Julian D., Dorothy D. Origins and evolution of antibiotic resistance. Microbiology and molecular biology reviews. 2010; 74 (3): 417–433. doi: 10.1128/MMBR.00016-10.

10. Liu Y., Wang H., Yang J., Zeng J., Sun G.M. Virome of respiratory secretion from children with unknown etiological acute respiratory disease revealed recombinant human parechovirus and other significant viruses. Virol J. 2021; 18 (1): 122. doi: 10.1186/s12985-021-01586-0.

11. Clinical guidelines: Influenza in adults. Available at: https://cr.minzdrav.gov.ru/recomend/749_1 (accessed February 17, 2022). (in Russian)

12. Golovacheva E.G., Afanasyeva O.I., Goncharova E.S., Bykovskaya A.G., Davletgareeva D.V., Apryatina V.A. Possibilities of therapeutic correction of ENT pathology associated with COVID-19 in children on an outpatient basis. Vestnik Oto-Rino-Laringologii. 2021; 86 (6): 69–73. doi: https://doi.org/10.17116/otorino20218606169. (in Russian, in English)

13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65 (1–2): 55–63. doi: 10.1016/0022-1759(83)90303-4.